Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27705072 | 0.85 | PTPN1 (0.49) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| SCHEMBL17294845 | 0.84 | MRGPRX4 (0.49) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| SCHEMBL4238088 | 0.84 | KAT6A (0.54) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| SCHEMBL1646172 | 0.82 | MRGPRX4 (0.48) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL3416101 | 0.82 | HMGB1 (0.51) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| SCHEMBL2611568 | 0.82 | NPC1 (0.41) | MRGPRX4ALDH1A1LMNAGAAHPGD | |
| SCHEMBL2886555 | 0.82 | PARP1 (0.44) | ALDH1A1ALOX15LMNAGAAHPGD | |
| SCHEMBL542766 | 0.82 | KDM4E (0.41) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 | |
| SCHEMBL336107 | 0.80 | ALDH1A1 (0.60) | ALBHMGB1ALDH1A1ALOX15NR4A1 | |
| SCHEMBL16720596 | 0.80 | FFAR1 (0.48) | MRGPRX4ALBHMGB1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-2452931-B1 | METHOD FOR PREPARING TRICYCLIC DERIVATIVES | JE IL PHARMACEUTICAL CO LTD (KR) | 2017-05-17 | — | — | EP | disclosed |
| EP-2452931-B1 | METHOD FOR PREPARING TRICYCLIC DERIVATIVES | JE IL PHARMACEUTICAL CO LTD (KR) | 2017-05-17 | — | — | EP | disclosed |
| US-20120101296-A1 | METHOD FOR PREPARING TRICYCLIC DERIVATIVES | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2012-04-26 | — | — | US | disclosed |
| EP-1646608-B1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2011-03-02 | — | — | EP | disclosed |
| CN-100393698-C | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO LTD (KR) | 2008-06-11 | — | — | CN | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| EP-1646608-A4 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-11-22 | — | — | EP | disclosed |
| CN-1826316-A | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-08-30 | — | — | CN | disclosed |
| EP-1646608-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL Pharmaceutical Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004113281-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | MRGPRX4 3953/4885ALB 1192/4885HMGB1 3389/4885 |
| US-20120101296-A1 | METHOD FOR PREPARING TRICYCLIC DERIVATIVES | NISCH, CA3, CYP51A1 | MRGPRX4 2529/4885ALB 3224/4885HMGB1 3678/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | MRGPRX4 2002/4885ALB 4605/4885HMGB1 339/4885 |
| US-20230002412-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | PADI4, PADI2, PADI1 | MRGPRX4 2002/4885ALB 4605/4885HMGB1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.